DK3177624T3 - Imidazopyridazinforbindelser - Google Patents

Imidazopyridazinforbindelser Download PDF

Info

Publication number
DK3177624T3
DK3177624T3 DK15760263.2T DK15760263T DK3177624T3 DK 3177624 T3 DK3177624 T3 DK 3177624T3 DK 15760263 T DK15760263 T DK 15760263T DK 3177624 T3 DK3177624 T3 DK 3177624T3
Authority
DK
Denmark
Prior art keywords
imidazopyridazine compounds
imidazopyridazine
compounds
Prior art date
Application number
DK15760263.2T
Other languages
Danish (da)
English (en)
Inventor
Thomas Allen Chappie
Matthew Merrill Hayward
Christopher John Helal
Erik Alphie Lachapelle
Nandini Chaturbhai Patel
Simone Sciabola
Patrick Robert Verhoest
Joseph Michael Young
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54065405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3177624(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3177624T3 publication Critical patent/DK3177624T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK15760263.2T 2014-08-06 2015-07-23 Imidazopyridazinforbindelser DK3177624T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033684P 2014-08-06 2014-08-06
US201562157129P 2015-05-05 2015-05-05
PCT/IB2015/055597 WO2016020786A1 (en) 2014-08-06 2015-07-23 Imidazopyridazine compounds

Publications (1)

Publication Number Publication Date
DK3177624T3 true DK3177624T3 (da) 2019-07-01

Family

ID=54065405

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15760263.2T DK3177624T3 (da) 2014-08-06 2015-07-23 Imidazopyridazinforbindelser

Country Status (32)

Country Link
US (4) US9598421B2 (cg-RX-API-DMAC7.html)
EP (1) EP3177624B1 (cg-RX-API-DMAC7.html)
JP (3) JP6506833B2 (cg-RX-API-DMAC7.html)
KR (1) KR102061952B1 (cg-RX-API-DMAC7.html)
CN (1) CN106795165B (cg-RX-API-DMAC7.html)
AP (1) AP2017009744A0 (cg-RX-API-DMAC7.html)
AU (2) AU2015298378B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017001334A2 (cg-RX-API-DMAC7.html)
CA (1) CA2899294C (cg-RX-API-DMAC7.html)
CO (1) CO2017000980A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170035A (cg-RX-API-DMAC7.html)
CU (1) CU20170007A7 (cg-RX-API-DMAC7.html)
DK (1) DK3177624T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000034A (cg-RX-API-DMAC7.html)
EA (1) EA031201B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17007336A (cg-RX-API-DMAC7.html)
ES (1) ES2733502T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20196950B (cg-RX-API-DMAC7.html)
HU (1) HUE044040T2 (cg-RX-API-DMAC7.html)
IL (2) IL250478B (cg-RX-API-DMAC7.html)
MD (1) MD20170011A2 (cg-RX-API-DMAC7.html)
MX (1) MX376283B (cg-RX-API-DMAC7.html)
PE (1) PE20170295A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500095A1 (cg-RX-API-DMAC7.html)
PL (1) PL3177624T3 (cg-RX-API-DMAC7.html)
PT (1) PT3177624T (cg-RX-API-DMAC7.html)
SG (1) SG11201700243YA (cg-RX-API-DMAC7.html)
SV (1) SV2017005381A (cg-RX-API-DMAC7.html)
TN (1) TN2017000031A1 (cg-RX-API-DMAC7.html)
TW (2) TWI577681B (cg-RX-API-DMAC7.html)
UY (1) UY36257A (cg-RX-API-DMAC7.html)
WO (1) WO2016020786A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6505023B2 (ja) 2013-02-19 2019-04-24 ファイザー・インク Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CN106795165B (zh) 2014-08-06 2019-09-10 辉瑞公司 咪唑并哒嗪化合物
ES2775674T3 (es) * 2016-02-23 2020-07-27 Pfizer Compuestos de 6,7-dihidro-5H-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11370769B2 (en) 2017-09-07 2022-06-28 Board Of Regents Of The University Of Nebraska TRPC5 inhibitors and methods of using same
WO2019197632A1 (en) * 2018-04-13 2019-10-17 Healx Limited Treatment of fragile x syndrome
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
WO2020190793A1 (en) * 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing
PL4031552T3 (pl) 2019-09-16 2025-03-17 Takeda Pharmaceutical Company Limited Pochodne azolowo-skondensowanych pirydazyn-3(2h)-onów
KR20220086607A (ko) * 2019-10-21 2022-06-23 에스케이바이오팜 주식회사 발달 장애의 예방, 경감 또는 치료를 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도
CN112194660B (zh) * 2020-10-20 2021-12-03 常州大学 一种pde2抑制剂苯基吡唑并嘧啶类化合物及其制备方法

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
JPH08295667A (ja) * 1995-04-27 1996-11-12 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
AU779516B2 (en) 1999-06-28 2005-01-27 Janssen Pharmaceutica N.V. Respiratory syncytial virus replication inhibitors
IL150594A0 (en) 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
MXPA02008145A (es) 2000-02-24 2004-04-05 Univ Washington Anticuerpos humanizados que secuestran al peptido beta amiloide.
ATE300540T1 (de) 2000-04-27 2005-08-15 Yamanouchi Pharma Co Ltd Imidazopyridin-derivate
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
AU2002239764B2 (en) 2000-11-03 2007-06-21 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
WO2003000697A1 (en) 2001-06-22 2003-01-03 Takeda Chemical Industries, Ltd. Furoisoquinoline derivative, process for producing the same, and use
ES2242036T3 (es) 2001-06-27 2005-11-01 MERCK FROSST CANADA & CO. Inhibidores pde4 de arilquinolina 8-sustituida.
WO2003002511A1 (en) 2001-06-29 2003-01-09 Nikken Chemicals Co., Ltd. Cycloalkenone derivative
WO2003008396A1 (en) 2001-07-16 2003-01-30 Nikken Chemicals Co., Ltd. Optically active oxazine derivative
WO2003008392A1 (de) 2001-07-18 2003-01-30 Merck Patent Gmbh 4-(benzyliden-amino)-3-(methylsulfanyl) -4h-(1, 2, 4) triazin-5-on derivate mit pde -iv hemmender und tnf-antagonistischer wirkung zur behandlung von herzkrankheiten und allergien
WO2003008373A1 (de) 2001-07-19 2003-01-30 Merck Patent Gmbh Tyrosinhydrazide
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
GB0118373D0 (en) 2001-07-27 2001-09-19 Glaxo Group Ltd Novel therapeutic method
TWI221838B (en) 2001-08-09 2004-10-11 Tanabe Seiyaku Co Pyrazinoisoquinoline compound or naphthalene compound
EP1285922A1 (en) 2001-08-13 2003-02-26 Warner-Lambert Company 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
FR2828693B1 (fr) 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
CA2456985A1 (en) 2001-08-15 2003-02-27 Icos Corporation 2h-phthalazin-1-ones and methods for use thereof
AU2002333193A1 (en) 2001-08-15 2003-03-03 Leo Pharma A/S A pharmaceutical composition for dermal application
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
JO2311B1 (en) 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
GB0122031D0 (en) 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
US20050014762A1 (en) 2001-09-19 2005-01-20 Rolf Beume Combination
AU2002337105B2 (en) 2001-09-19 2008-03-20 Takeda Gmbh Combination of a NSAID and a PDE-4 inhibitor
WO2003035650A1 (en) 2001-09-25 2003-05-01 Takeda Chemical Industries, Ltd. Entry inhibitor
MXPA04003007A (es) 2001-10-02 2004-07-15 Upjohn Co Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
GB0123951D0 (en) 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US7235579B2 (en) 2001-10-16 2007-06-26 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
EP2336133A1 (en) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
CZ2004516A3 (cs) 2001-10-31 2004-08-18 Merckápatentágmbh Inhibitor fosfodiesterázy typu @Ź jeho kombinace s jinými drogami a jeho použití
WO2003037900A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Pyrazolopyrimidines
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
US7141572B2 (en) 2001-11-05 2006-11-28 Merck Patent Gesellschaft Hydrazono-malonitriles
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
US20030092706A1 (en) 2001-11-09 2003-05-15 Johannes Barsig Combination
IS7221A (is) 2001-11-15 2004-04-15 Memory Pharmaceuticals Corporation Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
US20050101000A1 (en) 2002-12-11 2005-05-12 Isis Pharmaceuticals Inc. Modulation of phosphodiesterase 4B expression
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
PL377769A1 (pl) 2002-10-09 2006-02-20 Rinat Neuroscience Corp. Sposób leczenia choroby Alzheimera z zastosowaniem przeciwciał skierowanych przeciw peptydowi beta amyloidu i ich kompozycje
AU2003283303A1 (en) 2002-11-08 2004-06-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
EP1615697A2 (en) 2003-04-11 2006-01-18 Novo Nordisk A/S New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
DK1615647T3 (da) 2003-04-11 2010-04-06 High Point Pharmaceuticals Llc Farmaceutisk anvendelse af kondenserede 1,2,4-triazoler
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
MXPA05013478A (es) * 2003-06-10 2006-03-09 Pfizer Combinaciones terapeuticas.
WO2004110996A1 (en) 2003-06-19 2004-12-23 Pfizer Products Inc. Nk1 antagonist
AU2004253543B2 (en) 2003-07-01 2009-02-19 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
FR2857966A1 (fr) 2003-07-24 2005-01-28 Aventis Pharma Sa Produits aryl-heteroaromatiques, compositions les contenant et utilisation
US20050020587A1 (en) 2003-07-25 2005-01-27 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
EP1668024A4 (en) 2003-09-29 2008-07-02 Topigen Pharma Inc OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES INCLUDING INFLAMMATORY SUFFERING
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
EP1720847A1 (en) 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
CA2565965A1 (en) 2004-05-06 2006-07-27 Plexxikon, Inc. Pde4b inhibitors and uses therefor
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
EP2298807A3 (en) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
US7605168B2 (en) 2004-09-03 2009-10-20 Plexxikon, Inc. PDE4B inhibitors
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
EP1804792A1 (en) 2004-09-20 2007-07-11 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
CA2580852A1 (en) 2004-09-21 2006-03-30 Synta Pharmaceutical Corp. Compounds for inflammation and immune-related uses
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
DE102004054634A1 (de) 2004-11-12 2006-05-18 Schwarz Pharma Ag Azaindolcarboxamide
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
US20100130737A1 (en) 2005-02-18 2010-05-27 Takeda Pharmaceutical Company Limited Regulating Agent of GPR34 Receptor Function
GB0503955D0 (en) 2005-02-25 2005-04-06 Glaxo Group Ltd Novel compounds
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
AU2006245416B2 (en) 2005-05-12 2012-02-23 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
WO2006126082A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
CA2607499C (en) 2005-06-22 2010-11-30 Pfizer Products Inc. Histamine-3 receptor antagonists
WO2007013673A1 (en) * 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
EP1945639A1 (en) 2005-11-04 2008-07-23 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
EP2007749A2 (en) 2006-03-13 2008-12-31 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
GB0605462D0 (en) 2006-03-17 2006-04-26 Glaxo Group Ltd Novel compounds
WO2007122466A1 (en) 2006-04-21 2007-11-01 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
WO2008006051A2 (en) 2006-07-07 2008-01-10 Govek Steven P Bicyclic heteroaryl inhibitors of pde4
DE602007011773D1 (de) 2006-08-04 2011-02-17 Merz Pharma Gmbh & Co Kgaa Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
WO2008033739A2 (en) * 2006-09-12 2008-03-20 Neurogen Corporation Benzimidazole carboxamide derivatives
WO2008045664A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Heterocyclic pde4 inhibitors as antiinflammatory agents
WO2008045663A2 (en) 2006-10-06 2008-04-17 Kalypsys, Inc. Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents
US20080102475A1 (en) 2006-10-13 2008-05-01 Zhengyan Kan Alternatively spliced isoform of phosphodiesterase 4B (PDE4B)
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
AU2008208653B2 (en) 2007-01-22 2012-11-22 Pfizer Products Inc. Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
CA2691512A1 (en) 2007-08-10 2009-02-19 H. Lundbeck A/S Heteroaryl amide analogues
US8431608B2 (en) 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
GB2461702A (en) 2008-07-08 2010-01-13 Dyson Technology Ltd Hand drying apparatus
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
ES2710701T3 (es) 2008-09-24 2019-04-26 Basf Se Compuestos de pirazol para el control de plagas de invertebrados
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US8552051B2 (en) 2009-03-20 2013-10-08 H. L. Hall & Sons Limited Use of pharmaceutical compositions containing mesembrenone
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
EP2504340A1 (en) 2009-11-25 2012-10-03 Merz Pharma GmbH & Co. KGaA Crystalline forms of substituted pyrazolopyrimidines
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
EP2549874A4 (en) 2010-03-23 2013-10-02 High Point Pharmaceuticals Llc SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
JP6505023B2 (ja) 2013-02-19 2019-04-24 ファイザー・インク Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
US9193736B2 (en) * 2013-06-11 2015-11-24 Janssen Pharmaceutica, Nv PDE 10a inhibitors for the treatment of type II diabetes
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
CN106795165B (zh) 2014-08-06 2019-09-10 辉瑞公司 咪唑并哒嗪化合物

Also Published As

Publication number Publication date
MD20170011A2 (ro) 2017-08-31
PL3177624T3 (pl) 2019-09-30
CR20170035A (es) 2017-04-28
SV2017005381A (es) 2017-09-13
SG11201700243YA (en) 2017-02-27
EP3177624A1 (en) 2017-06-14
TWI629276B (zh) 2018-07-11
TW201713666A (zh) 2017-04-16
KR20170040299A (ko) 2017-04-12
US10669279B2 (en) 2020-06-02
US20190322674A1 (en) 2019-10-24
UY36257A (es) 2016-04-01
CO2017000980A2 (es) 2017-04-28
ES2733502T3 (es) 2019-11-29
TW201609743A (zh) 2016-03-16
CN106795165A (zh) 2017-05-31
US20160039828A1 (en) 2016-02-11
MX376283B (es) 2025-03-07
AU2018253590A1 (en) 2018-11-22
IL250478A0 (en) 2017-03-30
US10077269B2 (en) 2018-09-18
JP2021105002A (ja) 2021-07-26
MX2017001565A (es) 2017-04-27
ECSP17007336A (es) 2018-03-31
TWI577681B (zh) 2017-04-11
JP2017523209A (ja) 2017-08-17
BR112017001334A2 (pt) 2017-11-14
CA2899294A1 (en) 2016-02-06
IL250478B (en) 2019-06-30
GEP20196950B (en) 2019-02-25
PE20170295A1 (es) 2017-03-30
PT3177624T (pt) 2019-07-11
US9598421B2 (en) 2017-03-21
TN2017000031A1 (en) 2018-07-04
KR102061952B1 (ko) 2020-01-02
AU2015298378A1 (en) 2017-02-02
AU2015298378B2 (en) 2018-08-02
JP7074903B2 (ja) 2022-05-24
US20170145022A1 (en) 2017-05-25
JP2019163256A (ja) 2019-09-26
US20180346475A1 (en) 2018-12-06
DOP2017000034A (es) 2017-03-15
EA031201B1 (ru) 2018-11-30
HUE044040T2 (hu) 2019-09-30
EP3177624B1 (en) 2019-05-01
CA2899294C (en) 2018-07-10
EA201700042A1 (ru) 2017-07-31
JP6506833B2 (ja) 2019-04-24
AP2017009744A0 (en) 2017-02-28
WO2016020786A1 (en) 2016-02-11
CN106795165B (zh) 2019-09-10
PH12017500095A1 (en) 2017-05-22
CU20170007A7 (es) 2017-06-05
IL266108A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
LT3134402T (lt) 4-amino-imidazochinolino junginiai
LT3197883T (lt) Nauji junginiai
DK3183051T3 (da) Væske-til-luftmembranenergivekslere
DK4242916T3 (da) Forstøver
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
DK3222714T3 (da) Phytasemutanter
DK3119396T3 (da) Muscarinreceptoragonister
EP3230438C0 (en) N-GLYCOSYLATION
DK3177624T3 (da) Imidazopyridazinforbindelser
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK3183340T3 (da) Termolabile exonukleaser
BR112016030730A2 (pt) Composto
DE112015001664A5 (de) Betätigungsaktuator
CL2016002165A1 (es) Compuestos de aminocarbonilcarbamato
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
DE112015005041A5 (de) Gargerätevorrichtung
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3110439T3 (da) Pcsk9-vacciner
DE102014000623A8 (de) Halbhohlnietelement
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
DK3009858T3 (da) Skyradar
BR112016027901A2 (pt) Compostos
DE112015001633A5 (de) Betätigungsaktuator
DK3447493T3 (da) Proteinrettede ortologer